A Phase II Study of Revlimid in Combination with Rituximab as Initial Treatment for Patients with Indolent Non-Hodgkin’s Lymphoma (NHL)
The goal of this clinical research study is to learn if revlimid (lenalidomide) in combination with rituximab in previously untreated indolent non-Hodgkin's lymphoma can control the disease. The safety of this combination will also be studied.
Disease Group: Lymphoma
Treatment Agent: Lenalidomide,Rituximab
Treatment Location: Only at MD Anderson
Estimatated Length of Stay in Houston: N/A
Return Visit: Check-up visits day 1 of all cycles. Patients will be evaluated every 3 months for one year, every 6 months for 1 year and then yearly with CT neck, thorax, abdomen, and pelvis and other studies as recommended by the treating physician.
Home Care: None
Primary objectives To evaluate the overall response rate of lenalidomide in combination with rituximab in previously untreated indolent non-Hodgkin’s lymphoma (NHL). Secondary study objectives To evaluate the toxicity of lenalidomide in combination with Rituximab in previously untreated indolent non-Hodgkin’s lymphoma. Primary Endpoint To determine the number of CR, and PR. Secondary Endpoints Determine the type, frequency, severity, and relationship of adverse events to lenalidomide and rituximab.
IRB Review and Approval Date: 06/10/2008
Recruitment Status: Closed
Projected Accrual: N/A
1) Understand and voluntarily sign an informed consent form.
2) Age >/= 18 at the time of signing the informed consent form.
3) Able to adhere to the study visit schedule and other protocol requirements.
4) Untreated indolent non-Hodgkin’s lymphoma stage III-IV including small lymphocytic lymphoma, marginal zone lymphoma, grade 1 or 2 follicular lymphoma. (prior radiation for localized disease allowed).
5) At least one measurable lesion according to the International workshop standardized response criteria for non-Hodgkin’s lymphomas (IWG) greater than 1.5cm.
6) ECOG performance status of </= 2 at study entry.
7) Laboratory test results within these ranges: Absolute neutrophil count >/= 1.5 x 10^9/L; Platelet count >/=100 x 10^9/L; Serum creatinine </= 2.0 mg/dL; Total bilirubin </=1.5 mg/dL; AST (SGOT) and ALT (SGPT) </=2 x ULN or </=5 x ULN if hepatic metastases are present.
8) Disease free of prior malignancies for >/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast, or localized prostate cancer treated with curative intent.
9) All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
10) Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 -14 days prior to and again within 24 hours of prescribing lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing.
11) Men must agree to use a latex condom during sexual contact with a female of child bearing potential even if they have had a successful vasectomy.
12) For patients with bulky disease (tumors >5cm) must be able to take aspirin (81 mg or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin.
1) Any serious medical condition, laboratory abnormality, or psychiatric
illness that would prevent the subject from signing the informed consent form.
2) Pregnant or breast feeding females.
3) Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
4) Use of any chemotherapy or experimental therapy within 28 days of enrollment.
5) Known hypersensitivity to thalidomide.
6) The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
7) Any prior use of lenalidomide.
8) Concurrent use of other anti-cancer agents or experimental treatments.
9) Known positive for HIV or infectious hepatitis type B or C. (Hepatitis B core antibody can be positive if Hep B surface antigen is negative and no HBV DNA in blood, indicating a cleared infection.)